Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Multicenter real-world outcomes in limited stage (LS) diffuse large B-cell lymphoma (DLBCL) treated with abbreviated immunochemotherapy

Blood (2025) 146 (Supplement 1): 471.

https://doi.org/10.1182/blood-2025-471

Published: 2025

Journal Articles

Treatment patterns and outcomes of primary central nervous system lymphoma treated with high-dose methotrexate with or without autologous stem cell transplantation or whole brain radiation in the rea-world setting

Yifan Pang, Caroline Horne, Danielle Boselli, Allison Karabinos, Nicole Serapin, Stephanie Begley, Rupali Bose, LeAnne Kennedy, Ashley Sumrall, Roy Strowd, Glenn Lesser, Rakhee Vaidya, Mary Beth Seegars, Dianna Howard, Ryan Jacobs, Bei Hu, Tamara Moyo, Steven Park, Nilanjan Ghosh

Blood (2025) 146 (Supplement 1): 8064.

https://doi.org/10.1182/blood-2025-8064

Published: 2025

Journal Articles

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study

Blood blood.2025028848.

https://doi.org/10.1182/blood.2025028848

Published: 2025

Journal Articles

CAR-T Cell Subsets and Immune Repertoire Are Associated with Immune-Related Adverse Events and Efficacy after CD19 CAR T-Cell Therapy in B Cell Lymphoma

David M Foureau, Fei Guo, Erik Broemsen, Tahj Jones, Anna Ivanina-Foureau, Ryan Jacobs, Bei Hu, Tamara K Moyo, Yifan Pang, Steven I. Park, Lawrence J. Druhan, Ariel Bell, Nilanjan Ghosh

Blood (2024) 144 (Supplement 1): 2053.

https://doi.org/10.1182/blood-2024-205720

Published: 2024

Journal Articles

Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Using Real-World Data

Lihua E. Budde, Adam J. Olszewski, Bei Hu, Nikesh Shah, Connie Lee Batlevi, Shen Yin, Iris To, Michael C. Wei, Martine Kallemeijn, Victor Orellana-Noia, Lisa Musick, Natasha Shamas, Navdeep Pal, Ashwini Shewade, Jason R. Westin

Blood (2024) 144 (Supplement 1): 2373.

https://doi.org/10.1182/blood-2024-194340

Published: 2024

Journal Articles

Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy

Blood (2024) 144 (Supplement 1): 2669.

https://doi.org/10.1182/blood-2024-200958

Published: 2024

Journal Articles

Myeloid Derived Suppressor Cell Kinetics in Peripheral Blood Correlate with Efficacy and Toxicity of CAR T Cell Therapy in Relapsed or Refractory B Cell Lymphoma

David M Foureau, Hamid Ehsan, Fei Guo, Tahj Jones, Ryan W Jacobs, Bei Hu, Tamara K. Moyo, Yifan Pang, Steven I. Park, Lawrence J. Druhan, Ariel Bell, Nilanjan Ghosh

Blood (2023) 142 (Supplement 1): 1640.

https://doi.org/10.1182/blood-2023-187085

Published: 2023

Journal Articles

Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T-Cell (CART) Therapy in Diffuse Large B-Cell Lymphoma (DLBCL)

Hamid Ehsan, Ferdous Ahmed, Tamara K. Moyo, Bei Hu, Ryan W Jacobs, Yifan Pang, Steven I. Park, Vishal Shroff, Victoria Boseman, Travis Beam, Jennifer Elder, Nilanjan Ghosh

Blood (2023) 142 (Supplement 1): 7393.

https://doi.org/10.1182/blood-2023-186984

Published: 2023

Journal Articles

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Blood (2022) 140 (Supplement 1): 573–576.

https://doi.org/10.1182/blood-2022-163371

Published: 2022

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study

Blood (2022) 140 (Supplement 1): 6623–6626.

https://doi.org/10.1182/blood-2022-157761

Published: 2022

Journal Articles

Mogamulizumab-Associated Rash (MAR) Correlates with Longer Progression Free Survival in Cutaneous T Cell Lymphoma (CTCL)

Bei Hu, Shebli Atrash, Leah Cohen, Stefan K. Barta, Yumeng Zhang, Lubomir Sokol, Amy Ayers, Luis E Malpica Castillo, Steven R Hwang, N. Nora Bennani, David Wada, Aung M Tun, Tamara K. Moyo, Nilanjan Ghosh, Michi M Shinohara

Blood (2022) 140 (Supplement 1): 1488–1490.

https://doi.org/10.1182/blood-2022-166887

Published: 2022

Journal Articles

CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 1481–1484.

https://doi.org/10.1182/blood-2022-160090

Published: 2022

Journal Articles

Very Few Interventions after Tumor Lysis Monitoring in Patients with Chronic Lymphocytic Leukemia Who Are Started on Venetoclax in the Real-World Setting- Suggests Less Intensive Monitoring Maybe Safe for Low-Risk Patients

Ashley Matuszfisher, Rupali Bose, Danielle Boselli, Gray Magee, Tommy Chen, Bei Hu, Tamara K. Moyo, Amy Soni, Steven I. Park, Edward A. Copelan, Belinda Avalos, James T Symanowski, Derek Raghavan, Ryan Jacobs, Nilanjan Ghosh

Blood (2021) 138 (Supplement 1): 1557.

https://doi.org/10.1182/blood-2021-145714

Published: 2021

Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

Blood (2020) 136 (Supplement 1): 28–30.

https://doi.org/10.1182/blood-2020-134611

Published: 2020

Journal Articles

Minorities Do Not Have Worse Outcomes for Diffuse Large B Cell Lymphoma (DLBCL) If Optimally Managed

Bei Hu, MD, Tommy Chen, Danielle Boselli, MS, Rupali Bose, MS, MBA, James T. Symanowski, PhD, Derek Raghavan, MDPhDFACP,FRACP, Amy Soni, MD, Steven I Park, MD, Belinda R Avalos, MD, Edward A Copelan, Ryan Jacobs, MD, Nilanjan Ghosh, MD PhD

Blood (2019) 134 (Supplement_1): 425.

https://doi.org/10.1182/blood-2019-123998

Published: 2019

Journal Articles

Higher Incidence of Hemorrhagic Cystitis after Haploidentical Compared to Matched Sibling Donor Transplantation

Srinivasa Reddy Sanikommu, MD, Olivia Copelan, BA, Jiaxian He, MS, Candace M. Butler, MSPH, Michael R. Grunwald, MD, Nilanjan Ghosh, MD PhD, Jing Ai, MD, Thomas G. Knight, MD, Brittany Ragon, MD, Ryan Jacobs, MD, Bei Hu, Saad Z. Usmani, MD, James T Symanowski, PhD, Zainab Shahid, MD

Blood (2018) 132 (Supplement 1): 3380.

https://doi.org/10.1182/blood-2018-99-119612

Published: 2018

Journal Articles

Optimal Timing of Allogeneic Stem Cell Transplantation (Allo-SCT) for Chronic Myeloid Leukemia (CML) Patients in the Tyrosine Kinase Inhibitor (TKI) Era

Bei Hu, Xiao Lin, ^, Hans C. Lee, MD, Xuelin Huang, PhD, Rebecca Slack, MS, Elias J. Jabbour, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MBBS, Guillermo Garcia-Manero, MD, Richard E Champlin, MD, Zhen-Huan Hu, MPH, Kwang Woo Ahn, PhD, Ying Lee, MD, Uday Popat, MD, Ronald Sobecks, MD, Edwin Alyea, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Wael Saber, MD MS

Blood (2017) 130 (Supplement 1): 4582.

https://doi.org/10.1182/blood.V130.Suppl_1.4582.4582

Published: 2017

Journal Articles

The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Bei Hu, MD, Anas Younes, MD, Linda Claret, Lei Feng, MS, Jason R. Westin, MD, Nathan Fowler, MD, Sattva Neelapu, MD, Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Felipe Samaniego, MD, Luis E. Fayad, MD, Loretta J. Nastoupil, MD, Amanda R Copeland, RN, MSN, CNS, Michelle A Fanale, MD, Yasuhiro Oki, MD

Blood (2016) 128 (22): 1833.

https://doi.org/10.1182/blood.V128.22.1833.1833

Published: 2016

Journal Articles

A Predominant Mutation in Regulatory Region of SERPINC1 Gene and Venous Thrombosis

Bei Hu, Qingyun Wang, Liang Tang, PhD, Yu Hu, Han Liu

Blood (2015) 126 (23): 4669.

https://doi.org/10.1182/blood.V126.23.4669.4669

Published: 2015

Journal Articles

Thrombomodulin Gene Mutations Associated with Thromboembolic Diseases

Qingyun Wang, Liang Tang, PhD, Bei Hu, Yu Hu, Han Liu

Blood (2015) 126 (23): 3497.

https://doi.org/10.1182/blood.V126.23.3497.3497

Published: 2015

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Multicenter real-world outcomes in limited stage (LS) diffuse large B-cell lymphoma (DLBCL) treated with abbreviated immunochemotherapy

Treatment patterns and outcomes of primary central nervous system lymphoma treated with high-dose methotrexate with or without autologous stem cell transplantation or whole brain radiation in the rea-world setting

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study

CAR-T Cell Subsets and Immune Repertoire Are Associated with Immune-Related Adverse Events and Efficacy after CD19 CAR T-Cell Therapy in B Cell Lymphoma

Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Using Real-World Data

Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy

Myeloid Derived Suppressor Cell Kinetics in Peripheral Blood Correlate with Efficacy and Toxicity of CAR T Cell Therapy in Relapsed or Refractory B Cell Lymphoma

Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T-Cell (CART) Therapy in Diffuse Large B-Cell Lymphoma (DLBCL)

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Mogamulizumab-Associated Rash (MAR) Correlates with Longer Progression Free Survival in Cutaneous T Cell Lymphoma (CTCL)

CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas

Very Few Interventions after Tumor Lysis Monitoring in Patients with Chronic Lymphocytic Leukemia Who Are Started on Venetoclax in the Real-World Setting- Suggests Less Intensive Monitoring Maybe Safe for Low-Risk Patients

Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

Minorities Do Not Have Worse Outcomes for Diffuse Large B Cell Lymphoma (DLBCL) If Optimally Managed

Higher Incidence of Hemorrhagic Cystitis after Haploidentical Compared to Matched Sibling Donor Transplantation

Optimal Timing of Allogeneic Stem Cell Transplantation (Allo-SCT) for Chronic Myeloid Leukemia (CML) Patients in the Tyrosine Kinase Inhibitor (TKI) Era

The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

A Predominant Mutation in Regulatory Region of SERPINC1 Gene and Venous Thrombosis

Thrombomodulin Gene Mutations Associated with Thromboembolic Diseases

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only